Size : 1mLx10mM(inDMSO)
Synonyms:
| Description | Potassium iodide is used as the treatment of overactive thyroid and as protection of the thyroid gland from the influences of radiation from swallowed or inhaled radioactive iodine. It may be used after accidental exposure to radioactive iodine or before and after administration of medicine containing radioactive iodine. |
| In vitro | Iodine induces abnormal morphologic changes of cells, inhibited cell proliferation, and increases apoptosis rate in rat aorta endothelial cells. Iodine also reduces the activity of SOD, GSH-Px, and concentrations of GSH and increases the concentrations of MDA and protein carbonyl in a dose-dependent manner. Excess iodine decreased the activity of eNOS and increased the activity of iNOS and the expression of ICAM-1 and VCAM-1 in culture medium. Excess iodine exposure increases oxidative stress, causes damage of vascular endothelial cells, and altered the expression of adhesion factors and the activity of NOS. [1] Potassium iodide increases avidity of some immune reactions including C-mediated cell lysis mediated by altered access of C-binding receptors. [2] Potassium iodide (≥50 mM) increases lipid peroxidation in concentration-dependent manner. Potassium iodide (25 mM) reduces Fenton reaction-induced lipid peroxidation. [3] Potassium iodide is able to eliminate E faecalis from bovine root dentin when used with a 15-minute contact time. [4] |
| In vivo | Potassium Iodide decreases Schiff's bases (SB) concentrations in liver and lung homogenates after the administration of PTU but, unexpectedly, the level of SB increases in kidney homogenates of Wistar rats. [5] |
| Molecular Weight | 166.01 |
| Formula | IK |
| Cas No. | 7681-11-0 |
| Smiles | [K+].[I-] |
| Relative Density. | 1.7 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 30 mg/mL (180.71 mM), Sonication is recommended. DMSO: 31 mg/mL (186.74 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
